PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and chemotherapy for:
PERJETA® (pertuzumab) is a prescription medicine approved for use in combination with Herceptin® (trastuzumab) and docetaxel in people who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
PERJETA may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).
Receiving PERJETA during pregnancy can result in the death of an unborn baby and birth defects.
The most common side effects of PERJETA when given with Herceptin and chemotherapy as part of an early breast cancer regimen before surgery are:
Side effects may vary based on chemotherapy regimen.
The most common side effects of PERJETA when given with Herceptin and chemotherapy as part of an early breast cancer regimen after surgery are:
The most common side effects of PERJETA when given with Herceptin and docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PERJETA.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
Early Breast Cancer
KADCYLA is a prescription medicine used as an adjuvant (after surgery) treatment for HER2-positive early breast cancer when the patient has taken neoadjuvant (before surgery) treatment including a taxane and trastuzumab (Herceptin®) and there is cancer remaining in the tissue removed during surgery.
Patients are selected for therapy based on an FDA-approved test for KADCYLA.
Metastatic Breast Cancer
KADCYLA is a prescription medicine used to treat HER2-positive breast cancer that has spread to other parts of the body (metastatic breast cancer) after prior treatment with trastuzumab (Herceptin®) and a taxane. Prior treatment could have been for the initial treatment of breast cancer or for the treatment of cancer that had spread to other parts of the body.
Patients are selected for therapy based on an FDA-approved test for KADCYLA.
Liver problems
Heart problems
Pregnancy
Contact your doctor right away if you experience symptoms associated with these side effects.
Lung problems
Infusion-related reactions
Serious bleeding
Low platelet count
Nerve damage
Skin reactions around the infusion site
The most common side effects in people taking KADCYLA for early breast cancer are:
The most common side effects seen in people taking KADCYLA for metastatic breast cancer are:
You are encouraged to report side effects to Genentech and the FDA. You may contact Genentech by calling 1-888-835-2555. You may contact the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.
Talk to a healthcare professional for more information about the benefits and risks of KADCYLA.
Please see full Prescribing Information for Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
PHESGO® (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a prescription medicine approved for use in combination with chemotherapy for:
PHESGO is a prescription medicine approved for use in combination with docetaxel in adults who have HER2-positive breast cancer that has spread to different parts of the body (metastatic) and who have not received anti-HER2 therapy or chemotherapy for metastatic breast cancer.
PHESGO may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure).
Receiving PHESGO during pregnancy can result in the death of an unborn baby and birth defects.
PHESGO may cause serious lung problems.
The most common side effects of PHESGO when given with chemotherapy as part of an early breast cancer regimen are:
The most common side effects of PHESGO when given with docetaxel for treatment of breast cancer that has spread to other parts of the body (metastatic) are:
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
Talk to a healthcare professional for more information about the benefits and risks of PHESGO.
Please see full Prescribing Information for additional Important Safety Information, including most serious side effects.
If you cannot afford your medication, visit genentech-access.com/patient for financial assistance information.
Thank you for your interest.
The HERConnection support program is only available to people receiving treatment with a Genentech medication.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.